Reyes GN, Miranda DG

Language: Spanish
References: 22
Page: 9-13
PDF size: 166.24 Kb.

ABSTRACT

Breast cancer is the most common malignancy in women, in the history different methods have been developed for monitoring and diagnosis of the disease, such as tumor markers which are defined as substances produced by normal cells, which increase their production in the presence of malignant cells. In general, tumor markers are used in the screening, diagnosis and monitoring of some types of cancer, but a high concentration of a tumor marker may suggest the presence of cancer, this fact alone is not sufficient for diagnosis. The tumor marker used for breast cancer are CA 15-3 and carcinoembryonic antigen. Serum levels of CA 15-3 in healthy patients and in those with early disease show no difference; however in patients with advanced or metastatic breast cancer it is used to assess response to chemotherapy or progression of the disease.

REFERENCES

1. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006; 52 (3): 345-351.

2. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965; 122 (3): 467-481.

3. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer. 2002; 86 (8): 1217-1222.

4. Stieber P, Nagel D, Blankenburg I, Heinemann V, Untch M, Bauerfeind I et al. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-a retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta. 2015; 448: 228-231.

5. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008; 19 (4): 675-681.

6. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer. 1994; 30A: 2082-2084.

7. Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006; 6: 269.

8. Yonemori K, Katsumata N, Noda A, Uno H, Yunokawa M, Nakano E et al. Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. J Cancer Res Clin Oncol. 2008; 134 (11): 1199-1206.

9. Hashimoto K, Yonemori K, Katsumata N, Shimizu C, Hirakawa A, Hirata T et al. Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy. Ann Oncol. 2010; 21 (11): 2195-2200.

10. Coveney EC, Geraghty JG, Sherry F, McDermott EW, Fennelly JJ, O’Higgins NJ et al. The clinical value of CEA and CA 15-3 in breast cancer management. Int J Biol Markers. 1995; 10 (1): 35-41.

11. Geng B, Liang MM, Ye XB, Zhao WY. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Mol Clin Oncol. 2015; 3 (1): 232-236.

12. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25 (33): 5287-5312.

13. Shering SG, Sherry F, McDermott EW, O’Higgins NJ, Duffy MJ. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. 1998; 83 (12): 2521-2527.

14. Duffy MJ, Duggan C, Keane R, Hill ADK, McDermott E, Crown J et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem. 2004; 50 (3): 559-563.

15. Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat. 2002; 76 (2): 95-102.

16. Tampellini M, Berruti A, Bitossi R, Gorzegno G, Alabiso I, Bottini A et al. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat. 2006; 98 (3): 241-248.

17. Molina R, Augé JM, Escudero JM, Filella X, Zanon G, Pahisa J et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biol. 2010; 31 (3): 171-180.

18. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008; 54 (12): e11-e79.

19. Incoronato M, Mirabelli P, Catalano O, Aiello M, Parente C, Soricelli A et al. CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients. BMC Cancer. 2014; 14 (1): 356.

20. Pedersen AC, Sørensen PD, Jacobsen EH, Madsen JS, Brandslund I. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clin Chem Lab Med. 2013; 51 (7): 1511-1519.

21. Tampellini M, Berruti A, Gorzegno G, Bitossi R, Bottini A, Durando A et al. Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. Tumor Biol. 2001; 22 (6): 367-373.

22. Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One. 2015; 10 (7): e0133830.